Literature DB >> 8980920

Weibull function fits to pharmacokinetic data of ribavirin in man.

X D Liu1, L Xie, K Q Han, G Q Liu.   

Abstract

Weibull function C = Bts-1exp(-lambda ts) was used to describe plasma concentration-time data of ribavirin in 6 healthy subjects following an i.v. dose of 600 mg. A good fit was found in each of the subjects, where the coefficients of determination r2 were > 0.99. The parameters estimated were as follows: B, 5.90 +/- 1.86 micrograms.h1-s; lambda, 0.607 +/- 0.156 h-s; and s, 0.339 +/- 0.085, respectively. The results were compared with those by triexponential function. By providing lower values of AIC and SD, as well as higher values of r2, the Weibull function proved to be superior to triexponential function for data of 3 subjects. These results indicated that both Weibull function and triexponential function provided a good fit of plasma concentration-time data of ribavirin in man following an i.v. dose.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8980920     DOI: 10.1007/BF03189718

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  8 in total

1.  Pharmacokinetic stochastic model with Weibull-distributed residence times of drug molecules in the body.

Authors:  V K Piotrovskii
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

2.  High-performance liquid chromatography (HPLC) assay for ribavirin and comparison of the HPLC assay with radioimmunoassay.

Authors:  G G Granich; D J Krogstad; J D Connor; K L Desrochers; C Sherwood
Journal:  Antimicrob Agents Chemother       Date:  1989-03       Impact factor: 5.191

3.  [A non-linear method and its program for calculating pharmacokinetic parameters].

Authors:  Y C Yang; G Chen; L Yuan
Journal:  Zhongguo Yao Li Xue Bao       Date:  1983-12

4.  Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations.

Authors:  K Yamaoka; T Nakagawa; T Uno
Journal:  J Pharmacokinet Biopharm       Date:  1978-04

5.  [Two aspects about curve fitting in pharmacokinetics; weighting of experimental data and discrimination between linear compartmental models (author's transl)].

Authors:  Y L Zeng
Journal:  Yao Xue Xue Bao       Date:  1980-09

6.  Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide.

Authors:  R W Sidwell; J H Huffman; G P Khare; L B Allen; J T Witkowski; R K Robins
Journal:  Science       Date:  1972-08-25       Impact factor: 47.728

7.  Ribavirin disposition in high-risk patients for acquired immunodeficiency syndrome.

Authors:  O L Laskin; J A Longstreth; C C Hart; D Scavuzzo; C M Kalman; J D Connor; R B Roberts
Journal:  Clin Pharmacol Ther       Date:  1987-05       Impact factor: 6.875

8.  In vitro effect of 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (virazole, ICN 1229) on deoxyribonucleic acid and ribonucleic acid viruses.

Authors:  J H Huffman; R W Sidwell; G P Khare; J T Witkowski; L B Allen; R K Robins
Journal:  Antimicrob Agents Chemother       Date:  1973-02       Impact factor: 5.191

  8 in total
  1 in total

Review 1.  Nanomedicines in the treatment of patients with hepatitis C co-infected with HIV--focus on pegylated interferon-alpha.

Authors:  Heinz Zoller; Wolfgang Vogel
Journal:  Int J Nanomedicine       Date:  2006
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.